Business Wire

New Partnership Ensures AMRA’s Body Composition Analysis Will Be Easily Accessible via Siemens Healthineers Digital Ecosystem

Del

AMRA, the international leader in body composition analysis, and Siemens Healthineers have announced a new agreement that will see AMRA’s cloud-based, body composition analysis integrated into Siemens Healthineers Digital Ecosystem. Designed to deliver pioneering innovation whilst helping healthcare professionals deliver economic efficiencies, the partnership will be showcased at the annual Healthcare Information and Management Systems Society (HIMSS) conference and exhibition.

Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards digitalizing healthcare. Its Digital Ecosystem provides an open and secured environment which effectively integrates knowledge from a global and diverse network of healthcare stakeholders. To date almost 2,000 institutions from roughly 50 countries are already part of this Digital Ecosystem, continuously deriving insights based on innovative applications and services. The integration of AMRA’s body composition analysis will offer users an additional layer of analytics.

AMRA is the first in the world to transform images from a 6-minute whole body MRI scan into 3D-volumetric fat and muscle measurements, enabling outstanding accuracy and precision when assessing volume and distribution of fat and muscles, as well as metabolic status. This standardized, automated method offers a precise, cost-effective way to understand our bodies far beyond what is commonly used today. AMRA’s mission is to establish a new global standard in body composition analysis and confront global health challenges by enhancing the evidence base needed to predict and prevent disease.

“We are very excited to welcome AMRA to our Digital Ecosystem. The spectrum of members' data, capabilities, digital offerings and access points to the Digital Ecosystem keeps growing and allows healthcare providers worldwide to harness the power of healthcare going digital. We will generate unprecedented insights through our own offerings as well as through innovative digital health partners like AMRA. The goal is to help customers deliver value based care with better outcomes at lower costs”, said Alexander Lippert, Head of Digital Ecosystem at Siemens Healthineers.

Tommy Johansson, Chief Executive Officer of AMRA, commented, “We are excited that AMRA’s body composition analysis will be easily accessible through the Digital Ecosystem and to users of Siemens Healthineers MRI scanners. Through this partnership, we will be working closely with a driven and innovative team, which is digitalizing healthcare and making deeper insights available to healthcare providers globally.”

Renowned for its showcasing of cutting-edge products and solutions, the HIMSS conference (5-9th March 2018) is the industry’s largest educational program and exhibition, facilitating a network of over 45,000 professionals to congregate and collaborate in order to tackle the world’s biggest health and technology challenges.

-ENDS-

Notes to editor:
About Siemens Healthineers Digital Ecosystem: The Digital Ecosystem from Siemens Healthineers provides an open and secured environment for digitalizing healthcare. It effectively integrates and interconnects data and knowledge from a global and diverse network of healthcare stakeholders. Digital offerings developed by members of the Siemens Healthineers Digital Ecosystem will help to increase decision making capabilities based on data-driven insights. A dedicated store for digital offerings from Siemens Healthineers and as well its partners will allow users to quickly assess the different offerings and the use cases they serve. It supports healthcare institutions to efficiently purchase and deploy digital health offerings within their setting. For more information, visit www.siemens.com/healthineers-digital-ecosystem

About AMRA: AMRA is the first in the world to transform images from a rapid, 6-minute whole body MRI scan into precise, 3D-volumetric fat and muscle measurements. AMRA’s cloud-based analysis service offers precise, automated insights that have far-reaching implications for the pharmaceutical industry, academic R&D and, soon, clinical practice. Headquartered in Sweden, AMRA was founded in 2010 as a spin-off of the Center for Medical Image Science and Visualization (CMIV), the Department of Biomedical Engineering (IMT) and the Department of Medicine and Health (IMH) at Linköping University, Sweden. For more information, visit www.amramedical.com

Contact information

AMRA
Chelsea Ranger
SVP Commercial & Market Strategy
chelsea.ranger@amramedical.com
or
Siemens Healthineers Digital Ecosystem
Julie Donhauser
+49 173 1858622
julie.donhauser@siemens-healthineers.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Mopria Powers IPP Print Solution in Windows 10 Update19.12.2018 08:00Pressemelding

The Mopria® Alliance, a global non-profit membership organization providing universal standards and solutions for print and scan, today announced that Microsoft, a member of the Mopria Alliance, has implemented an IPP printing solution based on the Mopria standard, in the latest version of the Windows 10 operating system. Mopria is a set of standards offering simple and seamless printing to millions of certified printers and multi-function printers. Beginning with Windows 10 October 2018 Update, Windows added support for Mopria certified printers. When users install a new printer and Windows Update is not available, Windows will automatically install the Mopria certified printers. This eliminates the need for users to install any additional software or drivers, allowing them to print easily, regardless of the printer’s brand. “Implementing the Mopria standard in the most recent Windows Update enables us to continue to modernize the printing process for our customers,” said David Lemson

Chugai’s Satralizumab Meets Primary Endpoint in Phase III Monotherapy Study in NMOSD19.12.2018 08:00Pressemelding

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that a phase III monotherapy study of satralizumab (development code: SA237), SAkuraStar Study (NCT02073279) for the treatment of neuromyelitis optica spectrum disorder (NMOSD), which currently has no approved treatments, has achieved the primary endpoint. The primary endpoint was time to first protocol-defined relapse in the double-blind period. A statistically significant reduction in the risk of relapse was confirmed in patients who received satralizumab, compared to those who received placebo. Furthermore, the safety profile of satralizumab was consistent with that seen in previous studies. Further details will be presented at a future medical meeting. “We are pleased that satralizumab showed benefits also in a monotherapy setting following the previous results as add-on to baseline treatment in patients with NMOSD,” said Dr. Yasushi Ito, Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit. “We wil

Chugai's Satralizumab Receives FDA Breakthrough Therapy Designation for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders19.12.2018 08:00Pressemelding

Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Chugai’s anti-interleukin-6 (IL-6) receptor humanized recycling antibody satralizumab, an investigational medicine for neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NMOSD). “Satralizumab is a recycling antibody created utilizing Chugai’s proprietary antibody engineering technologies. We are delighted by the FDA’s designation for this innovative antibody based on the results of a Chugai-initiated global Phase III study” said Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit, Dr. Yasushi Ito. “Satralizumab is designed to inhibit signaling of the inflammatory cytokine IL-6, which is known to play a role in the pathogenesis of NMO/NMOSD. We continue our efforts to hopefully bring satralizumab as a new treatment option as soon as possible to people living with this devastating disease

SES Successfully Placed EUR 400 Million Multi-Tranche Schuldschein Loan19.12.2018 07:50Pressemelding

SES S.A., the world’s leading satellite operator, has completed the syndication of Schuldschein Loans for a total amount of EUR 400 million, comprising a EUR 150 million 5.5-year floating tranche at Euribor 6 months plus 0.80% and a EUR 250 million 7-year fixed rate tranche with a coupon of 1.71%. SES is rated Baa2/BBB- (both with stable outlook). The Schuldschein loan was upsized from the initially marketed size and was placed with several European and Asian institutions. The proceeds will support SES’ general corporate purposes and the refinancing of existing debt maturities which include a USD 500 million 144A bond with a coupon of 2.5% and a final maturity date of 25 March 2019. Andrew Browne, Chief Financial Officer of SES, commented: “We are pleased to have secured this financing at very attractive terms and expanding our investor base while extending our debt maturity profile, where we now have no further senior debt maturities to be financed until early 2020.” BNP Paribas, ING

Bentall Kennedy and GreenOak Real Estate Announce Merger to Form Bentall GreenOak, Global Real Estate Investment Platform19.12.2018 07:39Pressemelding

Bentall Kennedy and GreenOak Real Estate (“GreenOak”) announced today the signing of an agreement to merge the two firms into a leading global real estate investment platform. The combined entity will be named Bentall GreenOak. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181218005992/en/ GreenOak Co-Founders, John Carrafiell and Sonny Kalsi, existing GreenOak senior management and GreenOak’s strategic partner Tetragon Financial Group Limited will all continue to hold significant ownership stakes in Bentall GreenOak. Bentall Kennedy’s senior management team will also acquire a meaningful ownership position in the combined firm. Bentall GreenOak will be majority-owned by Sun Life Financial (“Sun Life”) and will operate under Sun Life Investment Management, the alternative asset management arm of Sun Life. Sun Life has committed significant co-investment capital to support the growth of Bentall GreenOak and to enhance the fi

Sun Life Financial to Acquire Majority Stake in Bentall GreenOak19.12.2018 07:37Pressemelding

Sun Life Financial Inc. (“Sun Life Financial”) (TSX: SLF) (NYSE: SLF) today announced that it intends to merge Bentall Kennedy, its leading North American real estate and property management firm which Sun Life Financial acquired in 2015, with GreenOak Real Estate (“GreenOak”), a global real estate investment firm with approximately $14 billion (US$11 billion) in assets under management and nine offices globally. Sun Life Financial will acquire a majority stake in the combined Bentall Kennedy and GreenOak entity that will be named Bentall GreenOak and be part of Sun Life Investment Management. Senior management of Bentall GreenOak will include executives from both Bentall Kennedy and GreenOak. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181218005987/en/ “This transaction is right on strategy, broadening our asset management pillar by expanding the capabilities of our alternatives manager, Sun Life Investment Management,”